Genome & Company

Korea - SuwonBiotechnology8 H-1B visas (FY2023)

Focus: Genome & Company is a Korea-based biotechnology firm specializing in microbiome and antibody therapeutics, with a focus on gastroenterology and oncology indications. The company operates at a pre-commercial stage with a diversified pipeline spanning early-phase development.

Gastroenterology

Profile data last refreshed 2d ago · AI intelligence enriched 2w ago

Open Jobs

About Genome & Company

AI assessmentNot Hiring

No open roles listed right now. Follow Genome & Company to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

50 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Making Sense of a Positive Genetic Test Result for Huntington Disease

Huntington Disease

N/A

The Perceived Impact of Children s Risk Status for Hypertrophic Cardiomyopathy on Families: an Explo

Cardiovascular Disease

N/A

Help build intelligence for Genome & Company

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Access to emerging microbiome science and antibody platform technologies in a focused therapeutic area
100% H1B approval rate (8/8 approvals in 2023) signals strong visa sponsorship commitment
Opportunity to contribute to early-stage pipeline with multiple Phase 1-3 programs across oncology and immunology

Watch Out For

Zero active job postings indicate company is not actively hiring or is in restructuring mode
Pre-revenue biotech status creates uncertainty around funding runway and long-term stability
Limited public visibility—no financial data, publications, or recent news available for due diligence

Generated by Claude from Genome & Company's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Prospective Huntington At Risk Observational Study

Huntington Disease

N/A

The Association Between Microbiota, Endotoxaemia and the Host Obesity/ Insulin Resistance (MiPOOP St

Central Obesity

N/A

Clinical Trials (1)

NCT03665961The Association Between Microbiota, Endotoxaemia and the Host Obesity/ Insulin Resistance (MiPOOP Study)

N/A

UCAN CAN-DU: Canada-Netherlands Personalized Medicine Network in Childhood Arthritis and Rheumatic D

Juvenile Idiopathic Arthritis

N/A

Analysis of Prostate Cancer Short-Term Cultures Using Molecular Cytogenetic Methods

Prostate Cancer

N/A

Where Culture Meets Genetics: Exploring Latinas Causal Attributions of Breast and Colon Cancer and M

Colon Cancer

N/A

Sodium Chloride

Cardiovascular Disease

N/A

Genetic Analysis of Parkinson's Disease

Parkinson's Disease

N/A

Analysis of Data From the Women's Contraceptive and Reproductive Experiences (CARE) Study

Breast Cancer

N/A

Pharmacogenomics of Drug Safety in Multiple Sclerosis

Multiple Sclerosis

N/A

15-0 H20

Parkinson Disease

N/A

Clinical and Pathophysiological Investigations Into Erdheim Chester Disease

Myelofibrosis

N/A

Belimumab 1 mg/kg

Systemic Lupus Erythematosus

N/A

APOE Disclosure

Alzheimer's Disease

N/A

GeneSight Psychotropic

Schizophrenia

N/A

New Approaches for Empowering Studies of Asthma in Populations of African Descent

Asthma

N/A

Study to Understand the Genetic Risk of Developing an Immune Response After Blood Transfusions Among

Sickle Cell Disease

N/A

Identification of Prostate Cancer Genes

Prostate Cancer

N/A

Gene Analysis of Parkinson's Disease

Parkinson's Disease

N/A

Belimumab 1 mg/kg

Lupus Erythematosus, Discoid

N/A

Genetics of Obesity, Diabetes, and Heart Disease in African Diaspora Populations

Diabetes

N/A

Pharmacogenetic testing

Acute Pain

N/A

Pharmacogenetic testing

Depression

N/A

Genetic Analysis of Familial Melanoma

Melanoma

N/A

Perceptions of Thalassemia Major in Singapore: An Exploratory Study of Stigma

Thalassemia Major

N/A

Genetics of Rheumatoid Arthritis

Rheumatoid Arthritis

N/A

Genetic Analysis of Left-Right Axis Formations

Congenital Heart Disease

N/A

Disease Risk Assessment

Cardiovascular Diseases

N/A

Family Health History

Breast Cancer

N/A

Examining the Knowledge, Attitudes, and Beliefs of Sickle Cell Disease Patients, Parents of Patients

Sickle Cell Disease

N/A

Pharmacogenetic testing

Chronic Pain

N/A

Needle core biopsies

Triple Negative Breast Cancer

N/A

Pre-visit prep

Epilepsy; Seizure

N/A

loss of heterozygosity analysis

Colorectal Cancer

N/A

Childhood-Onset Essential Hypertension Natural History Study

Hypertension

N/A

Genomics, Environmental Factors and Social Determinants of Cardiovascular Disease in African-America

Heart Disease

N/A

Genetic Epidemiology of Lung Cancer

Lung Cancer

N/A

Informed Consent for Whole Genome Sequencing: Ideals and Norms Referenced by Early Participants

Coronary Artery Disease

N/A

Enhanced Internet DA

Breast Cancer

N/A

Predicting Development of SCAF in Device Patients

Atrial Fibrillation

N/A

Clinical Trials (1)

NCT02808260Predicting Development of SCAF in Device Patients

N/A

Transitional Life Events in Patients With Friedreich's Ataxia: Implications for Genetic Counseling

Friedreich Ataxia

N/A

Self Affirmation

Breast Cancer

N/A

Answer ALS: Individualized Initiative for ALS Discovery

Amyotrophic Lateral Sclerosis

N/A

Clinical Trials (1)

NCT02574390Answer ALS: Individualized Initiative for ALS Discovery

N/A

Timing of return of results

Chronic Kidney Disease

N/A

Exercise Programme

Early-stage Breast Cancer

N/A

Clinical Trials (1)

NCT05957068Breast Cancer Exercise Intervention Study

N/A

G-CSF

Graft-Versus-Host Disease

N/A

Clinical Trials (1)

NCT00001529Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives

N/A

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 36 clinical trials

Top TAs: Oncology, Cardiovascular, Metabolic Diseases

H-1B (2023): 8 approvals

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

14 pipeline

3 pipeline

3 pipeline

2 pipeline

2 pipeline

1 pipeline

Marketed

Pipeline

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub